In Sneed v. Talphera, Inc., 2025 WL 2406424 (9th Cir. Aug. 20, 2025), the United States Court of Appeals for the Ninth Circuit affirmed the dismissal of a securities fraud suit against Talphera, Inc. (formerly AcelRx...more
9/8/2025
/ Disclosure Requirements ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Marketing ,
Misrepresentation ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Rule 10b-5 ,
Securities Exchange Act of 1934 ,
Securities Fraud ,
Securities Litigation